TITLE

Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients

AUTHOR(S)
Minutolo, Roberto; Conte, Giuseppe; Cianciaruso, Bruno; Bellizzi, Vincenzo; Camocardi, Andrea; De Paola, Luigi; De Nicola, Luca
PUB. DATE
July 2012
SOURCE
Nephrology Dialysis Transplantation;Jul2012, Vol. 27 Issue 7, p2880
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Lower responsiveness to erythropoiesis-stimulating agents (ESA-R) predicts cardiovascular (CV) events. Whether ESA-R also affects the risk of end-stage renal disease (ESRD) is unknown. Methods We evaluated ESA-R in 194 consecutive chronic kidney disease (CKD) patients, regularly seen in outpatient nephrology clinics, who started erythropoiesis-stimulating agent (ESA) therapy between 2002–06. Exclusion criteria were causes of anaemia other than CKD or recent transfusion. ESA-R was calculated as (Hb1 − Hb0)/time/ESA dose (g/dL/month/10 μg/week of ESA). Patients were classified, from lower to higher tertile of ESA-R, as poor, intermediate and good responders. Time to ESRD was the primary outcome. Results Age was 64 ± 16 years, 48% were male, 34% had diabetes and 32% had CV disease, glomerular filtration rate (GFR) 24 ± 13 mL/min/1.73 m2 and proteinuria 0.6 g/dL (interquartile range 0.2–1.9). First ESA dose was 23.7 ± 10.8 μg/week; haemoglobin (Hb) increased from 9.9 ± 0.8 g/dL to 11.0 ± 1.2 g/dL at first control, obtained after 1.4 ± 0.4 months. These changes corresponded to an ESA-R of 0.37 ± 0.38 g/dL/month/10 μg/week of ESA and tertiles limits were 0.17 and 0.47. Poor responders were younger and had lower GFR and higher proteinuria than intermediate and good responders. During the first 6 months of ESA therapy, poor responders showed lower Hb levels and sustained longer periods of Hb level <11 g/dL. During follow-up (median 3.0 years), 99 patients reached ESRD. At multivariable Cox's analysis, poor responsiveness was associated with higher risk of ESRD (hazard ratio 2.49, 95% confidence interval 1.28–4.84). Conclusion ESA-R predicts renal prognosis in CKD patients followed in nephrology practice, where ESRD is the predominant outcome and ESA is commonly used at low dose.
ACCESSION #
82329429

 

Related Articles

  • Assessment of Iron Status in Anemic Children with Chronic Kidney Disease. Alzahrani, Ali K.; Alzahrani, Abdrahman; Al Nashar, Nihad A.; Mohamed, Hala A. // Egyptian Journal of Hospital Medicine;Jul2013, Vol. 52, p658 

    Background: Iron deficiency is the commonest cause of resistance to erythropoiesis stimulating agents (ESAs) in dialyzed children treated from anemia of chronic kidney disease (CKD). Aim of the work: This study was conducted in order to evaluate the significance of different biomarkers in...

  • Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Kuwahara, Michio; Hasumi, Syoko; Mandai, Shintaro; Tanaka, Tomomi; Shikuma, Satomi; Akita, Wataru; Mori, Yoshihiro; Sasaki, Sei // Clinical & Experimental Nephrology;Oct2014, Vol. 18 Issue 5, p755 

    Background: Erythropoiesis-stimulating agents (ESAs) are standard therapy for chronic kidney disease (CKD) patients with renal anemia. However, few studies have compared the effects of different ESAs on anemia in identical pre-dialysis CKD patients. Methods: Seventy-nine patients who switched...

  • Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients. Suttorp, Marit M.; Hoekstra, Tiny; Mittelman, Moshe; Ott, Ilka; Franssen, Casper F. M.; Dekker, Friedo W. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Introduction: Erythropoiesis-Stimulating Agents (ESA) are hypothesized to increase cardiovascular mortality in patients with chronic kidney disease. One of the proposed mechanisms is the elevation of blood pressure (BP) by ESA. Therefore, we aimed to determine whether the use of ESA was...

  • A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Qunibi, Wajeh Y.; Martinez, Carlos; Smith, Mark; Benjamin, Joseph; Mangione, Antoinette; Roger, Simon D. // Nephrology Dialysis Transplantation;May2011, Vol. 26 Issue 5, p1599 

    Background. Iron deficiency is a common cause of anaemia and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent chronic kidney disease (ND-CKD) patients. Current intravenous iron agents cannot be administered in a single high dose because of adverse effects....

  • Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. Hallan, Stein I.; Dahl, Ketil; Oien, Cecilia M.; Grootendorst, Diana C.; Aasberg, Arne; Holrnen, Jostein; Dekker, Friedo W. // BMJ: British Medical Journal (International Edition);11/18/2006, Vol. 333 Issue 7577, p1047 

    Objective: To find an effective screening strategy for detecting patients with chronic kidney disease and to describe the natural course of the disease. Design: Eight year follow-up of a cross sectional health survey (the HUNT II study). Setting: Nord-Trøndelag County, Norway Participants: 65...

  • Cardiorenal connection in chronic kidney disease. Ito, Sadayoshi // Clinical & Experimental Nephrology;Feb2012, Vol. 16 Issue 1, p8 

    Chronic kidney disease (CKD), as defined by reduced glomerular filtration rate (<60 ml/min/1.73 m) and/or the presence of renal damage for >3 months, is a significant threat for public health in modern societies. Recent epidemiological studies have demonstrated that CKD is a significant risk for...

  • Comparison of the MDRD Study and the CKD-EPI Study equations in evaluating trends of estimated kidney function at population level: findings from the National FINRISK Study. Juutilainen, Auni; Kastarinen, Helena; Antikainen, Riitta; Peltonen, Markku; Salomaa, Veikko; Tuomilehto, Jaakko; Jousilahti, Pekka; Sundvall, Jouko; Laatikainen, Tiina; Kastarinen, Mika // Nephrology Dialysis Transplantation;Aug2012, Vol. 27 Issue 8, p3210 

    Background There are no data comparing the Modification of Diet in Renal Disease (MDRD) Study and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Study equations in the evaluation of time-dependent trend of estimated glomerular filtration rate (eGFR) in the general population....

  • Strategy to estimate risk progression of chronic kidney disease, cardiovascular risk, and referral to nephrology: the EPIRCE Study. Gayoso-Diz, Pilar; Otero-González, Alfonso; Rodríguez-Álvarez, M. Xosé; García, Fernando; González-Quintela, Arturo; Martín-de Francisco, Ángel L. // Nefrologia;2013, Vol. 33 Issue 2, p223 

    Background: Although the prevalence of chronic kidney disease (CKD) is 10-14%, several prospective studies note a low rate of progression to end-stage renal disease (ESRD) in stages 3 and 4. A correct classification of risk of progression, based on demonstrated predictive factors, would allow...

  • CKD. Doyle, Matt // Pulse;2/1/2007, Vol. 67 Issue 4, p55 

    The article focuses on the medical research on patients with chronic kidney disease (CKD), conducted by renal services national service for the routine reporting of estimated glomerular filtration rate. The patients' population recommends a practice with 10,000 patients will be prone to have...

Share

Read the Article

Courtesy of AIRBUS FRANCE S.A.S.

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics